微机器人经林业发展局批准的机器人系统能够进行更安全、遥控的血管程序。 Microbot's FDA-cleared robotic system enables safer, remote-controlled vascular procedures.

微机器人医疗公司已经获得林业发展局对其LiBERTY 室内机器人系统的许可,这是第一个用于外围血管手术的单用途遥控机器人系统。 Microbot Medical Inc. has received FDA clearance for its LIBERTY® Endovascular Robotic System, the first single-use, remote-controlled robotic system for peripheral vascular procedures. 该系统100%成功地进行了导航研究,没有出现任何负面事件,医生的辐射照射减少了92%。 The system was 100% successful in navigation studies with zero adverse events and reduced radiation exposure for doctors by 92%. 这一许可使微型机器人能够进入美国市场,美国市场每年执行约250万项相关程序,并有可能在全球扩大。 This clearance allows Microbot to enter the U.S. market, which performs about 2.5 million relevant procedures annually, and potentially expand globally.